rebel Financial rebel Financial
← All Posts

Nurix Therapeutics, Inc.

May 16, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 Election of Class III Directors
1.01 Arthur T. Sands, M.D., Ph.D. Withhold
1.02 Roger Dansey, M.D. ✓ For
1.03 Paul M. Silva ✓ For
2 Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026. ✓ For
3 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. ✓ For
Attachments
📄
NRIX_Annual_Report_2025.pdf 2.7 MB
📄
NRIX_Proxy_Statement.pdf 0.4 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.